EPO906 Therapy in Patients With Prostate Cancer

Novartis

Status and phase

Completed

Phase 2

Conditions

Prostatic Neoplasms

Treatments

Drug: epothilone b

Study type

Interventional

Funder types

Industry

Identifiers

NCT00035113

CEPO906A2204

Details and patient eligibility

About

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.

Enrollment

48 patients

Sex

Male

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The following patients may be eligible for this study:

Patients with any histologically proven prostate cancer with measurable metastatic disease or PSA progression > 20ng/ml after initial hormonal therapy will be eligible
Patients must be maintained on androgen ablation therapy with a LHRH agonist or have undergone orchiectomy
Patients in whom bicalutamide or flutamide has been recently withdrawn must demonstrate progression of disease and be at least 6 weeks and 4 weeks respectively, beyond the discontinuation of such agents
Patients taking PC-SPES must discontinue therapy for a minimum of 4 weeks
For patients with disease progression defined solely by PSA increase: two consecutive rises in PSA measurement, over a 4-week period (each separated from the previous by 2 weeks) - the last measurement must be at least 50% greater than the nadir PSA achieved after the last therapeutic maneuver
For patients who discontinued bicalutamide therapy prior to study entry, a third rising PSA measurement is required 2 weeks from the second PSA measurement (i.e. over a 6 week period)
Must have a life expectancy of greater than three (3) months
Bilirubin must be within normal limits. Transaminases (SGOT and/or SGPT) may be up to 2.5 X institutional upper limit of normal if alkaline phosphatase is less than the upper limit of normal, or alkaline phosphatase may be up to 4 X upper limit of normal if transaminases are less than or equal to the upper limit of normal
For patients with disease progression defined by measurable disease: changes in measurable size of lymph nodes or parenchymal masses on physical or radiologic examination (bone scan findings are not adequate to assess measurable disease).

Exclusion criteria

The following patients are not eligible for the study:

Patients with symptomatic CNS metastases or leptomeningeal involvement
Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1
Patients with severe cardiac insufficiency
Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports
Patients who received palliative radiotherapy to tumors located centrally less than 4 weeks (28 days) prior to planned enrollment date (palliative radiotherapy to isolated peripheral bone metastases is allowed)
Patients experiencing hormone withdrawal syndrome, or are 28 days post-withdrawal of anti-androgen therapy (42 days for bicalutamide)
Patients who have had more than one prior chemotherapy regimen for hormone-resistant metastatic disease
Patients with disease measurable only by bone scan
Patients who have received corticosteroids within the past 28 days (may be waived with approval from Novartis)
History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer
Patients who have undergone major surgery for any cause less than 4 weeks prior to study entry
Patients with radiation therapy or chemotherapy within the last four weeks
Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae
HIV+ patients